MA56631B1 - Dérivés de n-methyl, n-(6-(methoxy)pyridazin-3-yl) amine en tant que modulateurs du autotaxin (atx) pour le traitement de maladies inflammatoires du système respiratoire - Google Patents
Dérivés de n-methyl, n-(6-(methoxy)pyridazin-3-yl) amine en tant que modulateurs du autotaxin (atx) pour le traitement de maladies inflammatoires du système respiratoireInfo
- Publication number
- MA56631B1 MA56631B1 MA56631A MA56631A MA56631B1 MA 56631 B1 MA56631 B1 MA 56631B1 MA 56631 A MA56631 A MA 56631A MA 56631 A MA56631 A MA 56631A MA 56631 B1 MA56631 B1 MA 56631B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridazin
- methoxy
- methyl
- autotaxin
- atx
- Prior art date
Links
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 title 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 title 2
- 150000001412 amines Chemical class 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 210000002345 respiratory system Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne des dérivés de n-méthyl, n-(6-(méthoxy)pyridazin-3- yl) amine servant de modulateurs de l'autotaxine (atx) pour le traitement de maladies inflammatoires des voies respiratoires ou fibrotiques, telles que par exemple, la maladie pulmonaire idiopathique (iff) ou la sclérose systémique (ssc). La présente invention concerne la préparation de composés donnés à titre d'exemple (par exemple, pages 57 à 75 ; exemples 1.1 à 5) ainsi que des données biologiques pertinentes de ceux-ci (par exemple, pages 15 à 21, tableaux 1 à 9). Un exemple de composé est, par exemple, l-(6-(4-(((6-((6-(trifluorométhyl) pyridin-3-yl)méthoxy)pyridazin-3-yl)amino)méthyl)phényl)-2,6- diazaspiro[3.3]heptan-2-yl)éthan-l-one (exemple 1.1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19187617 | 2019-07-22 | ||
| PCT/EP2020/070547 WO2021013830A1 (fr) | 2019-07-22 | 2020-07-21 | Dérivés de n-méthyl, n-(6-(méthoxy)pyridazin-3-yl) amine servant de modulateurs de l'autotaxine (atx) pour le traitement de maladies inflammatoires des voies respiratoires ou fibrotiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56631B1 true MA56631B1 (fr) | 2024-05-31 |
Family
ID=67438402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56631A MA56631B1 (fr) | 2019-07-22 | 2020-07-21 | Dérivés de n-methyl, n-(6-(methoxy)pyridazin-3-yl) amine en tant que modulateurs du autotaxin (atx) pour le traitement de maladies inflammatoires du système respiratoire |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11485727B2 (fr) |
| EP (2) | EP4003998B1 (fr) |
| JP (3) | JP2022541065A (fr) |
| KR (1) | KR20220038438A (fr) |
| CN (2) | CN118666853A (fr) |
| AR (1) | AR119453A1 (fr) |
| AU (1) | AU2020316643A1 (fr) |
| BR (1) | BR112021026887A2 (fr) |
| CA (1) | CA3145868A1 (fr) |
| CL (1) | CL2022000112A1 (fr) |
| CO (1) | CO2022000243A2 (fr) |
| CR (1) | CR20220022A (fr) |
| DK (1) | DK4003998T3 (fr) |
| DO (1) | DOP2022000008A (fr) |
| EC (1) | ECSP22003856A (fr) |
| ES (1) | ES2977909T3 (fr) |
| FI (1) | FI4003998T3 (fr) |
| HR (1) | HRP20240697T1 (fr) |
| HU (1) | HUE066770T2 (fr) |
| IL (1) | IL289788A (fr) |
| JO (1) | JOP20220012B1 (fr) |
| LT (1) | LT4003998T (fr) |
| MA (1) | MA56631B1 (fr) |
| MX (2) | MX2022000958A (fr) |
| PE (1) | PE20220964A1 (fr) |
| PH (1) | PH12022550154A1 (fr) |
| PL (1) | PL4003998T3 (fr) |
| PT (1) | PT4003998T (fr) |
| RS (1) | RS65498B1 (fr) |
| SI (1) | SI4003998T1 (fr) |
| TW (2) | TWI858098B (fr) |
| UA (1) | UA128544C2 (fr) |
| WO (1) | WO2021013830A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005445A2 (pt) * | 2018-10-29 | 2021-06-15 | Boehringer Ingelheim International Gmbh | piridazinas |
| US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
| CN114127054B (zh) | 2019-07-22 | 2024-04-09 | 勃林格殷格翰国际有限公司 | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 |
| TW202309035A (zh) * | 2021-04-14 | 2023-03-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為TRPA1抑制劑之咪唑并[4,5-d]噠嗪酮基衍生物 |
| KR102587919B1 (ko) * | 2022-07-22 | 2023-10-11 | 주식회사 넥스트젠바이오사이언스 | 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
| CN120917018A (zh) * | 2023-03-31 | 2025-11-07 | 株式会社次代生物科学 | 新的氮杂双环衍生物和包含其的用于抑制自分泌运动因子的药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008071646A1 (fr) * | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | Nouveaux dérivés pyridazines à activité antagoniste du récepteur mch et médicaments comprenant ces composés |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| WO2013061297A1 (fr) * | 2011-10-28 | 2013-05-02 | Pfizer Limited | Dérivés de pyridazine utiles en thérapie |
| RU2675818C2 (ru) | 2013-03-14 | 2018-12-25 | Галапаго Нв | Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств |
| EP3010922B1 (fr) | 2013-06-19 | 2017-03-15 | Galapagos NV | Nouveaux composés et compositions pharmaceutiques les comprenant pour le traitement de troubles inflammatoires |
| GB201503141D0 (en) * | 2015-02-03 | 2015-04-08 | Fosbel Inc | Integral self-supporting refractory checker brick modules for glass furnace regenerator structures, and methods of forming same |
| GB201603745D0 (en) * | 2016-03-04 | 2016-04-20 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
| WO2017192304A1 (fr) * | 2016-05-02 | 2017-11-09 | Inception 1, Inc. | Arylcarboxamides et leurs utilisations |
| KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| IL279702B2 (en) * | 2018-07-27 | 2024-05-01 | Mitsubishi Tanabe Pharma Corp | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same |
| BR112021005445A2 (pt) | 2018-10-29 | 2021-06-15 | Boehringer Ingelheim International Gmbh | piridazinas |
| US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
| CN114127054B (zh) | 2019-07-22 | 2024-04-09 | 勃林格殷格翰国际有限公司 | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 |
| US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
-
2020
- 2020-07-20 US US16/932,882 patent/US11485727B2/en active Active
- 2020-07-21 UA UAA202200670A patent/UA128544C2/uk unknown
- 2020-07-21 EP EP20743687.4A patent/EP4003998B1/fr active Active
- 2020-07-21 BR BR112021026887A patent/BR112021026887A2/pt unknown
- 2020-07-21 CN CN202410520327.5A patent/CN118666853A/zh active Pending
- 2020-07-21 TW TW109124572A patent/TWI858098B/zh active
- 2020-07-21 HU HUE20743687A patent/HUE066770T2/hu unknown
- 2020-07-21 LT LTEPPCT/EP2020/070547T patent/LT4003998T/lt unknown
- 2020-07-21 JP JP2022503996A patent/JP2022541065A/ja not_active Ceased
- 2020-07-21 ES ES20743687T patent/ES2977909T3/es active Active
- 2020-07-21 CN CN202080051863.5A patent/CN114206876B/zh active Active
- 2020-07-21 PT PT207436874T patent/PT4003998T/pt unknown
- 2020-07-21 HR HRP20240697TT patent/HRP20240697T1/hr unknown
- 2020-07-21 KR KR1020227005957A patent/KR20220038438A/ko active Pending
- 2020-07-21 FI FIEP20743687.4T patent/FI4003998T3/fi active
- 2020-07-21 WO PCT/EP2020/070547 patent/WO2021013830A1/fr not_active Ceased
- 2020-07-21 RS RS20240520A patent/RS65498B1/sr unknown
- 2020-07-21 EP EP24157589.3A patent/EP4364805A3/fr active Pending
- 2020-07-21 TW TW113133675A patent/TW202523660A/zh unknown
- 2020-07-21 MA MA56631A patent/MA56631B1/fr unknown
- 2020-07-21 AR ARP200102049A patent/AR119453A1/es unknown
- 2020-07-21 MX MX2022000958A patent/MX2022000958A/es unknown
- 2020-07-21 DK DK20743687.4T patent/DK4003998T3/da active
- 2020-07-21 PH PH1/2022/550154A patent/PH12022550154A1/en unknown
- 2020-07-21 PL PL20743687.4T patent/PL4003998T3/pl unknown
- 2020-07-21 CR CR20220022A patent/CR20220022A/es unknown
- 2020-07-21 AU AU2020316643A patent/AU2020316643A1/en active Pending
- 2020-07-21 SI SI202030415T patent/SI4003998T1/sl unknown
- 2020-07-21 CA CA3145868A patent/CA3145868A1/fr active Pending
- 2020-07-21 PE PE2022000105A patent/PE20220964A1/es unknown
-
2022
- 2022-01-12 IL IL289788A patent/IL289788A/en unknown
- 2022-01-14 CO CONC2022/0000243A patent/CO2022000243A2/es unknown
- 2022-01-17 CL CL2022000112A patent/CL2022000112A1/es unknown
- 2022-01-17 EC ECSENADI20223856A patent/ECSP22003856A/es unknown
- 2022-01-19 JO JOJO/P/2022/0012A patent/JOP20220012B1/ar active
- 2022-01-19 DO DO2022000008A patent/DOP2022000008A/es unknown
- 2022-01-21 MX MX2025000985A patent/MX2025000985A/es unknown
- 2022-09-23 US US17/934,625 patent/US20230100516A1/en not_active Abandoned
-
2023
- 2023-04-20 JP JP2023069392A patent/JP7559131B2/ja active Active
-
2024
- 2024-09-18 JP JP2024160665A patent/JP7797590B2/ja active Active
-
2025
- 2025-01-27 US US19/038,051 patent/US20260001863A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56631B1 (fr) | Dérivés de n-methyl, n-(6-(methoxy)pyridazin-3-yl) amine en tant que modulateurs du autotaxin (atx) pour le traitement de maladies inflammatoires du système respiratoire | |
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| EA200401282A1 (ru) | Пиридиноилпиперидины как агонисты 5-ht1f | |
| BR112022001176A2 (pt) | Derivados de 1-(6-(metoxi)piridazin-3-il)ciclopropano-1-carboxamida como moduladores de autotaxina (atx) para o tratamento de doenças inflamatórias das vias aéreas | |
| TNSN07393A1 (fr) | Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques | |
| PL177604B1 (pl) | Pochodne 5-aryloindolu | |
| MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
| MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
| BR0205602A (pt) | EnantiÈmero possuindo a configuração s na posição-4 dos seu anel pirazol de um composto, composição farmacêutica, método para a preparação de composições farmacêuticas, processo para a preparação de compostos, e, métodos de tratamento de distúrbios que envolvem neurotransmissão canabinóide | |
| MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
| MA30991B1 (fr) | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 | |
| MA34331B1 (fr) | Composés pyrazole comme inhibiteurs du récepteur sigma | |
| PH12022550176A1 (en) | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases | |
| Cohen et al. | Evolution of a strategy for the synthesis of structurally complex batzelladine alkaloids. Enantioselective total synthesis of the proposed structure of batzelladine F and structural revision | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| NO20055854L (no) | (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister | |
| DE60004654D1 (de) | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden | |
| Yu et al. | Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats | |
| MA31922B1 (fr) | Dérivés d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) | |
| MA38229B1 (fr) | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments | |
| BRPI0417844A (pt) | derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina | |
| Lin et al. | Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19 | |
| MA52375A1 (fr) | Inhibiteurs de cdk8/19 | |
| CN1878756A (zh) | 作为5－羟色胺－6配体的磺酰基四氢－3h－苯并(e)吲哚－8－胺化合物 |